Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12920005 | 0.90 | HPGD (0.75) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL17132595 | 0.86 | HPGD (0.65) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL620074 | 0.84 | POLB (0.66) | HPGDLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL23254707 | 0.84 | HPGD (0.63) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL12089756 | 0.84 | TSHR (0.67) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL14441177 | 0.84 | HPGD (0.63) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL12089923 | 0.83 | HPGD (0.62) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL26078949 | 0.83 | HPGD (0.61) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL104793 | 0.83 | HPGD (0.70) | HPGDRAB9ASMN1; SMN2NPC1LMNA | |
| SCHEMBL25753422 | 0.82 | MMP13 (0.59) | HPGDRAB9ASMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | ARRAY BIOPHARMA INC (US) | 2022-02-15 | — | — | US | disclosed |
| US-9133186-B2 | Hetero ring-fused imidazole derivative having AMPK activating effect | SHIONOGI & CO., LTD. (JP) | 2015-09-15 | — | — | US | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | SHIONOGI & CO., LTD. (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184240-A1 | HETERO RING-FUSED IMIDAZOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT | PRKAA1, PRKAA2, PRKAG1 | HPGD 2261/4885RAB9A 1895/4885SMN1; SMN2 4474/4885 |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | HPGD 225/4885RAB9A 1841/4885SMN1; SMN2 2328/4885 |
| US-11247990-B1 | Bicyclic fused pyridine compounds as inhibitors of TAM kinases | MAP3K1, MAP3K3, MAP3K2 | HPGD 3276/4885RAB9A 1582/4885SMN1; SMN2 3848/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | HPGD 2472/4885RAB9A 331/4885SMN1; SMN2 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.